NCT03502005View on ClinicalTrials.gov

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 30, 2019

Study Completion Date

December 30, 2019

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

bictegravir/emtricitabine/tenofovir alafenamide

Discontinue ATRIPLA® and initiate BIKTARVY®

Trial Locations (1)

33334

Midland Research Group, Inc, Oakland Park

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Midland Research Group, Inc.

OTHER